ClinicalTrials.govpublic full text
Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
type 2 diabetes mellitus (t2dm), atherosclerosis, major adverse cardiac and cerebrovascular events, cilostazol, aspirin, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 853022
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.